Evaluation of efficacy of Tofacitinib in COVID 19 patients - A prospective randomised study
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/12/038732
- Lead Sponsor
- Bangalore Medical College and Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. SARS Co V2 positivity to the nasal swab by RTPCR
2. Presence of radiological findings of pneumonia assessed by chest radiography and HRCT
3. Patients with eGFR 15-30 ml/min
4. PaO2/ FiO2 100-300 mmHg at ABG
Exclusion Criteria
1. Patients with active / latent tuberculosis
2. Patients with pre - existing AKI, EGFR < 15ml/min
3. Patients with deranged liver function test
4. Patients with history of chronic dialysis and renal transplant
5. Patients with history of thrombophlebitis and acute / chronic autoimmune disorder
6. Patients with serology positive
7. Patients on immunosuppressive drugs
8. Pregnant and lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Incidence and duration of non-invasive ventilation/ high flow oxygen <br/ ><br>2. Incidence and duration of invasive mechanical ventilation <br/ ><br>3. Frequency of adverse kidney events <br/ ><br>4. Number of days in ICU <br/ ><br>5. ICU mortality <br/ ><br>6. Hospital mortalityTimepoint: NEWS score baseline, and at 1week, 2 weeks <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method Frequency of adverse kidney eventsTimepoint: at 1 week and 2 weeks